Introduction
============

Lung cancer is the leading cause of cancer-related death worldwide. Accumulating evidence has demonstrated that tumor-infiltrating fibroblasts (also called cancer-associated fibroblasts \[CAFs\]) were significantly associated with survival of lung cancer patients. However, CAFs are a heterogeneous population, and hence it is important to distinguish among different subpopulations as they may play differential roles in tumor microenvironment (TME).[@b1-ott-11-5607] Tumor-infiltrating podoplanin^+^ fibroblasts, a new subset of CAFs identified recently, have been demonstrated to play specific and significant roles in human lung cancer.

Podoplanin, a well-conserved, mucin-type transmembrane protein, has exerted a variety of functions including regulation of organ development and cell motility.[@b2-ott-11-5607] Recent studies have indicated that podoplanin was often upregulated in CAFs in the tumor stroma.[@b3-ott-11-5607] Podoplanin^+^ fibroblasts are often among the early immune cells recruited to tumor sites in response to the stimuli and increase in the TME. In the last decades, multitudinous studies have associated podoplanin-positive CAFs and prognosis in lung cancer patients, but their results were controversial.[@b4-ott-11-5607] Thus, it needs in-depth assessment, and furthermore, the potential of these cells as an effective prognostic biomarker and targeted therapy is necessary to be explored.

Herein, we performed this meta-analysis to clarify the association between podoplanin^+^ fibroblast infiltration and outcomes such as overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in lung cancer patients, and thereby provided more evidence on the clinical value of podoplanin-positive CAFs as a prognostic biomarker for lung cancer.

Materials and methods
=====================

Search strategy
---------------

PubMed and EBSCO were searched for studies to evaluate the density of podoplanin-positive CAFs and survival in lung cancer patients from 1980 to April 15, 2018. The keywords adopted for search were (podoplanin \[Title/Abstract\] OR fibroblasts \[Title/Abstract\]) AND (lung \[Title/Abstract\] OR pulmonary \[Title/Abstract\]) AND (neoplasms \[Title/Abstract\] OR tumor \[Title/Abstract\] OR cancer \[Title/ Abstract\] OR carcinoma \[Title/Abstract\]).

Inclusion and exclusion criteria
--------------------------------

In this meta-analysis, the inclusion criteria were that studies included must have 1) been published as original articles; 2) investigated lung cancer patients; 3) detected podoplanin^+^ fibroblasts in primary tumor specimens with immunohistochemistry; 4) provided HRs with 95% CI, or Kaplan--Meier curves of podoplanin^+^ fibroblast density associated with OS, and/or DFS, and/or PFS; and 5) been published in English.

We excluded studies that were not published as research articles or were full texts such as commentary, case report, letters to editors, or conference abstracts. Studies that did not provide sufficient data to estimate HRs, or detected fibroblasts without using the marker "podoplanin", or exhibited metastatic infiltration were also excluded.

End points
----------

In this meta-analysis, OS and DFS were recorded as the primary and PFS as secondary end points. Individual studies defined cut-offs for podoplanin^+^ fibroblast density and classified patients into high- and low-density groups.

Data extraction
---------------

The authors GH and KZ independently reviewed and extracted data such as first author's name, number of patients, median age, time of follow-up, method applied to quantify podoplanin^+^ fibroblasts, and cut-off value to determine high density of these cells. OS, DFS, PFS, and clinicopathological data including TNM stage, and lymphatic, vascular, and pleural invasion were extracted from the text, tables, or Kaplan--Meier curves.

Quality assessment
------------------

The studies included in this meta-analysis were cohort studies. Two independent authors assessed the quality of the included studies with Newcastle--Ottawa Scale (NOS),[@b5-ott-11-5607] and achieved consensus for each item with the help of third author. The studies with score 6 or more were recorded as high-quality studies.

Statistical analysis
--------------------

We combined extracted data into meta-analyses with STATA 12.0 analysis software (Stata Corporation, College Station, TX, USA). Statistical heterogeneity was assessed with the chi-squared based *Q*-test or *I*^2^.[@b6-ott-11-5607] Data were pooled based on the random-effect model in the presence of heterogeneity,[@b7-ott-11-5607] otherwise, the fixed-effect model was applied.[@b8-ott-11-5607] Sensitivity analysis, Begg's funnel plot, and Egger's test[@b9-ott-11-5607] were employed to investigate the influence of each study on the pooled results and potential publication bias, respectively. All *P*-values were two-sided and values less than 0.05 were considered to be statistically significant.

Result
======

Search results and description of studies
-----------------------------------------

A total of 9,860 records were retrieved and the results are exhibited in [Figure S1](#SD1-ott-11-5607){ref-type="supplementary-material"}. We ultimately identified 12 studies including 1,802 lung cancer patients for the assessment of podoplanin-positive CAFs,[@b10-ott-11-5607]--[@b21-ott-11-5607] and then evaluated all these studies with the NOS. Characteristics of the included studies which satisfied the inclusion criteria and were suitable for data consolidation are shown in [Tables 1](#t1-ott-11-5607){ref-type="table"} and [S1](#SD5-ott-11-5607){ref-type="supplementary-material"}.

Meta-analyses
-------------

### Overall survival

The meta-analysis showed that the elevated density of podoplanin-positive CAFs was significantly associated with decreased OS (HR=1.66, 95% CI 1.20--2.30, *P*=0.002) in patients with lung cancer ([Figure 1](#f1-ott-11-5607){ref-type="fig"}).

In stratified analyses by pathologic types of lung cancer, as shown in [Figure 2](#f2-ott-11-5607){ref-type="fig"}, pooled results indicated that high density of podoplanin-positive CAFs was significantly associated with worse OS in lung adenocarcinoma (AC) (HR=1.81, 95% CI 1.29--2.53, *P*=0.001); Similar result was observed with regard to podoplanin-positive CAFs and OS in squamous cell carcinoma (SCC) of lung (HR=2.00, 95% CI 1.27--3.15, *P*=0.003), with little heterogeneity being observed (*I*^2^=31.8%, *P*=0.231).

### Disease-free survival and progression-free survival

Meta-analysis showed that podoplanin^+^ fibroblast infiltration was significantly associated with decreased DFS (HR=1.87, 95% CI 1.07--3.26, *P*=0.027) and PFS (HR=1.78, 95% CI 1.22--2.58, *P*=0.002) in lung cancer patients ([Figure 3](#f3-ott-11-5607){ref-type="fig"}).

As for DFS, in stratified analyses by pathologic types, we found that increased density of podoplanin^+^ fibroblasts within tumor was significantly associated with worse DFS in lung AC (HR=2.52, 95% CI 1.81--3.51, *P*=0.000), with no heterogeneity existing among included studies (*I*^2^=0.0%, *P*=0.689). Similar result was observed between podoplanin^+^ fibroblast infiltration and DFS in SCC of the lung (HR=2.33, 95% CI 1.45--3.74, *P*=0.000) ([Figure S2](#SD2-ott-11-5607){ref-type="supplementary-material"}).

We further investigated whether podoplanin-positive CAFs correlated with clinicopathological features such as lymph node metastasis and lymphatic invasion of lung cancer. We found that increased density of these cells was significantly associated with lymph node metastasis (OR=1.99, 95% CI 1.35--2.94, *P*=0.001); lymphatic (OR=2.10, 95% CI 1.06--4.13, *P*=0.032), vascular (OR=3.83, 95% CI 1.03--14.21, *P*=0.044), and pleural invasion (OR=2.19, 95% CI 1.03--4.64, *P*=0.041) ([Figure 4](#f4-ott-11-5607){ref-type="fig"}); and also with tumor size (OR=0.46, 95% CI 0.32--0.66, *P*=0.000) and smoking (OR=2.44, 95% CI 1.39--4.27, *P*=0.002) status, but not with age (dichotomized according to an age of 70 years) (OR=0.81, 95% CI 0.46--1.42, *P*=0.463) or tumor differentiation (OR=0.24, 95% CI 0.01--4.15, *P*=0.324) of patients ([Figure S3](#SD3-ott-11-5607){ref-type="supplementary-material"}).

### Sensitivity analysis

Sensitivity analysis indicated that each included study had no influence on the overall HR for OS or DFS ([Figure S4](#SD4-ott-11-5607){ref-type="supplementary-material"}).

### Publication bias

There was no publication bias existing between podoplanin-positive CAFs and OS (*P*=0.876) or DFS (*P*=0.491) in patients by Funnel plot and Egger's test.

Discussion
==========

Fibroblasts play a crucial role in maintaining the structural integrity of connective tissues by continuously secreting precursors of the extracellular matrix (ECM). In the past decades, although many studies have correlated podoplanin-positive CAFs with prognosis of lung cancer patients, their results were not consistent but rather controversial. In the present meta-analysis, we found that podoplanin^+^ fibroblast infiltration had a negative prognostic effect associated with survival in lung cancer, especially in AC and SCC of lung. In addition, increased density of podoplanin-positive CAFs was significantly associated with lymph node metastasis; lymphatic, vascular, and pleural invasion; tumor size, and smoking status. We believe that our study is the first to provide meaningful statistical evidence exhibiting the important prognostic value of podoplanin-positive CAFs as a cancer promoter in lung cancer patients.

We thought that the following reasons could possibly be responsible for the close association between increased podoplanin-positive CAFs and decreased survival of patients identified in this study: Activated fibroblasts are able to promote tumor cell invasion, proliferation, and survival through releasing growth factors, cytokines,[@b22-ott-11-5607] and ECM degrading proteases such as matrix metalloproteinases.[@b23-ott-11-5607] More importantly, podoplanin expressed in fibroblasts can enhance the ability of these cells to promote motility and survival of neighboring tumor cells through increased RhoA activity, especially in AC cells.[@b24-ott-11-5607] Podoplanin-positive CAFs can synthesize and release angiogenic factors including IL-8 and TNF-α as well as VEGF which promote neoangiogenesis, thereby facilitating tumor growth.[@b25-ott-11-5607] In addition, they can also produce varied amounts of immunosuppressive cytokines such as TGF-β1, IL-6, and IL-10 to inhibit antitumor immunity mediated by effector T cells,[@b25-ott-11-5607] recruit tumor-associated macrophages via CCL2 secretion, and decrease the activation of effector T cells through their acquisition of adhesion molecules such as intercellular adhesion molecule--1 (ICAM-1),[@b26-ott-11-5607] and thereby establishing immunosuppressive microenvironment. Thus, it is reasonable to conclude that the podoplanin-positive CAFs are able to promote tumor progression, thus decreasing survival. However, one included study reported that the presence of podoplanin-positive CAFs within tumor predicted favorable prognosis in high-grade neuroendocrine carcinomas,[@b14-ott-11-5607] suggesting that these cells might possess antitumor property. However, further investigation is needed to validate such result.

Previous studies have demonstrated that many cancer types are rich in CAFs, such as pancreatic cancer, and can facilitate a desmoplastic TME, hindering antitumor agents from infiltrating into tumor and thereby dampening treatment efficacy to a greater extent.[@b27-ott-11-5607] Researchers have developed several therapeutic strategies to target fibroblasts such as nano-delivery of fraxinellone and nanoparticle-mediated trapping of Wnt family member 5A to remodel the TME in preclinical studies, yielding somewhat promising results.[@b28-ott-11-5607],[@b29-ott-11-5607] We think our finding may provide a new strategy for effective lung cancer treatment.

There were some limitations in this study. First, morphometric analyses for podoplanin-positive CAFs used in individual included studies were not consistent. Second, there was only one study reporting the relevant data for OS in neuroendocrine carcinomas of the lung; therefore, we could not get a combined result for it. Finally, studies with negative results may not be published, which can cause potential publication bias.

In conclusion, increased density of podoplanin-positive CAFs leads to an unfavorable clinical outcome in lung cancer patients, implicating that it is a valuable prognostic biomarker and targeting it may have a potential for effective treatment.

Supplementary materials
=======================

###### 

Flowchart diagram of study selection.

###### 

Stratified analyses describing HRs of the association between podoplanin^+^ fibroblast infiltration and DFS.

**Abbreviation:** DFS, disease-free survival.

###### 

Forest plots indicating ORs of the association between podoplanin^+^ fibroblast infiltration and other clinicopathological features such as tumor size.

**Note:** Weights are from random-effects analysis.

###### 

Plots describing the influence of individual studies on the overall HRs for OS (**A**) and DFS (**B**) in lung cancer patients.

**Abbreviations:** DFS, disease-free survival; OS, overall survival.

###### 

Characteristics of the included studies for OR analysis of clinicopathological features

  Study                               Year   Tumor type                         No of patients   Age (\<70/≥70 years)     Podoplanin^+^ fibroblast density: high/low   Lymph node metastasis (yes/no)   Lymphatic invasion (yes/no)   Vascular invasion (yes/no)   Pleural invasion (yes/no)   Tumor size (≤3/\>3 cm)    Tumor differentiation (well-moderate/poor)   Smoking (yes/no)
  ----------------------------------- ------ ---------------------------------- ---------------- ------------------------ -------------------------------------------- -------------------------------- ----------------------------- ---------------------------- --------------------------- ------------------------- -------------------------------------------- ------------------------
  Kubouchi et al[@b31-ott-11-5607]    2018   Stage IA lung adenocarcinoma       158              H: (17/24); L: (55/62)   41/117                                       NR                               H: (18/23); L: (11/106)       NR                           NR                          NR                        H: (29/39); L: (109/8)                       H: (30/11); L: (42/75)
  Yurugi et al[@b32-ott-11-5607]      2017   Squamous cell carcinoma of lung    126              NR                       41/85                                        H: (11/30); L: (20/65)           H: (4/15); L: (22/63)         NR                           H: (22/19); L: (22/63)      H: (14/27); L: (42/43)    NR                                           H: (39/2); L: (82/3)
  Koriyamai et al[@b33-ott-11-5607]   2015   Lung adenocarcinoma                87               NR                       30/57                                        H: (19/11); L: (22/35)           H: (16/14); L: (25/32)        H: (29/1); L: (38/19)        NR                          NR                        NR                                           NR
  Takahashi et al[@b34-ott-11-5607]   2013   Neuroendocrine carcinomas oflung   115              H: (20/27); L: (41/27)   47/68                                        NR                               NR                            NR                           H: (14/33); L: (26/42)      NR                        NR                                           NR
  Neri et al[@b36-ott-11-5607]        2012   Stage III lung adenocarcinoma      112              NR                       51/61                                        NR                               H: (28/23); L: (41/20)        H: (33/18); L: (52/9)        H: (32/19); L: (37/24)      NR                        H: (34/14); L: (43/18)                       H: (32/19); L: (35/26)
  Nakasone et al[@b30-ott-11-5607]    2018   Lung adenocarcinoma                97               NR                       40/57                                        NR                               NR                            NR                           NR                          NR                        NR                                           H: (29/11); L: (25/32)
  Ito et al[@b37-ott-11-5607]         2012   Stage I lung adenocarcinoma        304              NR                       105/199                                      NR                               H: (35/70); L: (20/179)       H: (61/44); L: (23/176)      H: (39/66); L: (20/179)     H: (68/37); L: (161/38)   NR                                           NR
  Kitano et al[@b39-ott-11-5607]      2010   Lung cancer                        266              NR                       92/174                                       H: (41/51); L: (64/110)          H: (38/36); L: (78/75)        H: (36/36); L: (46/104)      NR                          NR                        NR                                           NR
  Kawase et al[@b40-ott-11-5607]      2008   Lung adenocarcinoma                177              H: (40/14); L: (84/39)   54/123                                       H: (23/31); L: (31/92)           H: (29/25); L: (47/76)        H: (43/11); L: (44/79)       H: (29/25); L: (31/92)      H: (23/31); L: (77/46)    NR                                           H: (35/19); L: (50/73)

**Abbreviations:** NR, not reported; H, high; L, low.
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![Forest plots describing HR of the association between podoplanin^+^ fibroblast infiltration and OS in lung cancer patients.\
**Note:** Weights are from random-effects analysis.\
**Abbreviation:** OS, overall survival.](ott-11-5607Fig1){#f1-ott-11-5607}
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**Note:** Weights are from random-effects analysis.\
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###### 

Main characteristics of the included studies

  Study                               Year   Tumor type                             No of patients   Male/female   Median age (range) (years)   Cut-offs                                           Podoplanin^+^ fibroblast density: high/low   Tumor stage   Median follow-up date (months)   Survival   Quality score (NOS)
  ----------------------------------- ------ -------------------------------------- ---------------- ------------- ---------------------------- -------------------------------------------------- -------------------------------------------- ------------- -------------------------------- ---------- ---------------------
  Nakasone et al[@b10-ott-11-5607]    2018   Lung adenocarcinoma                    97               51/46         (40, 85)                     ≥10% of spindle cells in the stroma                40/57                                        I--III        NR                               OS, DFS    6
  Kubouchi et al[@b11-ott-11-5607]    2018   Stage IA lung adenocarcinoma           158              76/82         68.8±9.5                     ≥10% of spindle-shaped cells in the stroma         41/117                                       IA--IB        82.5 (8, 151)                    OS, DFS    7
  Yurugi et al[@b12-ott-11-5607]      2017   Squamous cell carcinoma of lung        126              115/11        73.9±8.25                    ≥10% of spindle-shaped cells in the stroma         41/85                                        I--IIIA       48.0 (1, 137)                    OS, DFS    7
  Koriyamai et al[@b13-ott-11-5607]   2015   Lung adenocarcinoma                    87               54/33         64 (41, 78)                  ≥50% of spindle-shaped cells/0.0625 mm^2^          30/57                                        I--IV         NR                               OS, PFS    6
  Takahashi et al[@b14-ott-11-5607]   2013   Neuroendocrine carcinomas of lung      115              98/17         68 (22, 86)                  ≥50% of spindle-shaped cells/0.0625 mm^2^          47/68                                        I--IV         52.8                             OS, DFS    8
  Ono et al[@b15-ott-11-5607]         2013   Stage I lung squamous cell carcinoma   142              125/17        66 (58, 80)                  ≥50% of CAFs in the stroma                         44/98                                        IA--IB        62.4                             OS, DFS    7
  Neri et al[@b16-ott-11-5607]        2012   Stage III lung adenocarcinoma          112              64/48         65.5 (41, 83)                ≥10% of stromal fibroblasts/HPF                    51/61                                        III           84                               OS         7
  Ito et al[@b17-ott-11-5607]         2012   Stage I lung adenocarcinoma            304              139/165       \<65: 52%; ≥65: 48%          ≥10% of spindle cells in the stroma/0.0625 mm^2^   105/199                                      IA--IB        87 (5, 181)                      DFS        7
  Hoshino et al[@b18-ott-11-5607]     2011   Lung adenocarcinoma                    112              54/58         NR                           ≥10% of spindle cells in the stroma/0.0625 mm^2^   32/80                                        NR            ≥120                             OS, DFS    7
  Kitano et al[@b19-ott-11-5607]      2010   Lung adenocarcinoma                    157              182/84        65±9.7                       ≥10% of spindle cells in the stroma/0.0625 mm^2^   21/79                                        I--IV         NR                               OS         6
                                             Squamous cell carcinoma of lung        109              31/30         OS                                                                                                                                                                                     
  Kawase et al[@b20-ott-11-5607]      2008   Lung adenocarcinoma                    177              86/91         \<70: 70%; ≥70: 30%          ≥10% of spindle cells in the stroma                54/123                                       I--IV         117.6                            OS         8
  Yoshida et al[@b21-ott-11-5607]     2015   Lung adenocarcinoma                    106              63/43         (42, 85)                     ≥10% of spindle cells in the stroma                57/49                                        I--IV         NR                               PFS        6

**Notes:** Values in parenthesis indicate the shortest and longest time to follow up.

**Abbreviations:** NOS, Newcastle--Ottawa Scale; NR, not reported; CAF, cancer-associated fibroblasts; HPF, high power field; OS, overall survival; DFS, disease-free survival; PFS, progression-free survival.
